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Background.  We analytically characterized the past, present, and future levels and trends of the national herpes simplex virus 
type 2 (HSV-2) epidemic in the United States.
Methods. A population-level mathematical model was constructed to describe HSV-2 transmission dynamics and was fitted to 
the data series of the National Health and Nutrition Examination Survey.
Results. Over 1950–2050, antibody prevalence (seroprevalence) increased rapidly from 1960, peaking at 19.9% in 1983 in those aged 
15–49 years, before reversing course to decline to 13.2% by 2020 and 8.5% by 2050. Incidence rate peaked in 1971 at 11.9 per 1000 person-
years, before declining by 59% by 2020 and 70% by 2050. Annual number of new infections peaked at 1 033 000 in 1978, before declining 
to 667 000 by 2020 and 600 000 by 2050. Women were disproportionately affected, averaging 75% higher seroprevalence, 95% higher inci-
dence rate, and 71% higher annual number of infections. In 2020, 78% of infections were acquired by those 15–34 years of age.
Conclusions. The epidemic has undergone a major transition over a century, with the greatest impact in those 15–34 years of 
age. In addition to 47 million prevalent infections in 2020, high incidence will persist over the next 3 decades, adding >600 000 new 
infections every year.
Keywords.  genital herpes; genital ulcer disease; herpes simplex virus; HSV-2; incidence; mathematical model; neonatal herpes; 
prevalence.
Herpes simplex virus type 2 (HSV-2) is a globally prevalent sex-
ually transmitted infection [1–3] and the most common cause of 
genital ulcer disease [4]. An estimated 492 million persons had 
HSV-2 infection in 2016, equivalent to 13.2% of the world’s popu-
lation aged 15–49 years [5]. Infection is often latent and asympto-
matic, but with frequent reactivations and occasional symptomatic 
episodes causing ulcerative lesions in the genitalia and anus [6, 7]. 
Infection can cause other clinical disease such as neonatal herpes 
[8, 9], and its associated stigma can lead to depression [10] and 
anxiety [10]. HSV-2 infection is considered a principal cofactor 
in human immunodeficiency virus (HIV) transmission and ep-
idemic growth [11–13], and an effective proxy biomarker for 
sexual risk behavior and HIV epidemic potential [14–16].
National HSV-2 antibody prevalence (seroprevalence) 
studies in the United States (US) have been conducted regu-
larly for 4 decades and suggested a growing but then declining 
epidemic [17–22]. Despite an improved understanding of sero-
prevalence, a comprehensive characterization of the epidemic 
past, present, and future is still lacking. We aimed to fill this 
gap through mathematical modeling of HSV-2 transmission 
dynamics over a century, 1950–2050. We assessed the temporal 
evolution and varying sex and age distributions of seroprev-
alence, incidence rate, and annual number of new infections. 
The study aims to inform public health response and ongoing 
efforts to develop HSV preventive and therapeutic vaccines 
[23–27]. A major strength of this analysis is the methodolog-
ical approach, allowing rigorous unraveling of the epidemic’s 
history and dynamics, that is deep-rooted in 10 rounds of 
quality population-based and sex- and age-stratified data of the 
National Health and Nutrition Examination Survey (NHANES) 
conducted in the US [28].
METHODS
Mathematical Model
A deterministic compartmental model was developed to de-
scribe HSV-2 transmission in the US. Model equations and 
a schematic diagram describing the model are found in the 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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Supplementary Text and Supplementary Figure 1, respectively. 
The model was based on extension and adaptation of earlier 
models [11, 27, 29–31] and consisted of coupled nonlinear dif-
ferential equations that stratify the US population into com-
partments according to infection status and stage, sex, age, and 
sexual behavior. To reduce complexity, the model did not explic-
itly distinguish between different forms of sexual transmission.
HSV-2 natural history was divided into 3 stages: pri-
mary infection, latent infection, and infection reactivation 
(Supplementary Figure 1). Persons who acquired HSV-2 for 
the first time developed primary infection followed by la-
tent infection and reactivations. Those with latent infection 
episodically reactivated their infection, symptomatically or 
asymptomatically, and shed the virus during reactivation.
The model categorized the population into 5-year age groups. 
To account for heterogeneity in exposure risk/sexual risk be-
havior, the model further incorporated 5 sexual risk groups 
based on data of the age-dependent number of sexual partners 
over the last 12 months [28]. Distribution of risk of infection 
exposure across risk groups followed a power-law function in-
formed by network and modeling analyses [32–36].
Sexual mixing between age groups and risk groups ranged 
from fully assortative (choosing partners from own age or risk 
group) to proportionate (no preferential bias in choosing part-
ners) [37–39]. Force of infection was expressed in terms of 
sexual-partner acquisition rate, HSV-2 transmission probability 
per sexual act and per partnership, and mixing among age and 
risk groups. Temporal variation in the sexual-partner acquisi-
tion rate was incorporated to generate the observed historical 
patterns of infection.
A detailed description of the model is available in the 
Supplementary Materials. Analyses were conducted in 
MATLAB R2019a [40].
Model Parameterization
The model was parameterized using current data for HSV-2 
natural history and epidemiology. We used seroprevalence data 
from 10 rounds of the nationally representative population-
based NHANES surveys (1988–2016) that followed stand-
ardized analytical and laboratory procedures [28]. Testing 
for glycoprotein specific to HSV-2 (designated gG-2) in sera 
was implemented using solid-phase enzymatic type-specific 
immunodot assays [28]. The 1976–1980 round used different 
procedures and was included only in a sensitivity analysis.
NHANES standardized survey methods and analytic guide-
lines [41] were applied in extracting and analyzing demo-
graphic, sexual, and seroprevalence data including the 5-year 
seroprevalence age distribution and reported number of sexual 
partners in the last 12 months (0, 1, 2, 3, or ≥4 partners), in 
men and women, along with associated 95% confidence inter-
vals [28].
US demographics and trends (Supplementary Figure 2) were 
obtained from the United Nations World Population Prospects 
database [42].
Model parameter values and justifications are shown in 
Supplementary Table 1.
Model Fitting
The model was fitted to NHANES sex-specific, age-specific, 
and total seroprevalence time-series data for those 15–49 years 
old [28]. Data fitting was implemented using a nonlinear least-
squares fitting approach, as per previous work [31, 38, 39, 43, 
44]. Overall risk of exposure varied with time until a best fit of 
trend data was reached. Model-fitting details are shown in the 
Supplementary Materials.
Uncertainty and Sensitivity Analyses
We implemented 500 model runs applying Latin hypercube 
sampling from a multidimensional distribution of model 
parameters (Supplementary Table 1)—assuming ±40% un-
certainty around parameters’ point estimates, as informed by 
earlier work [31, 39, 45–47]. In each run, parameters’ values 
were randomly selected from their specified ranges, and the 
model was refitted to data. Means and 95% uncertainty inter-
vals were derived from resulting distributions for each pre-
dicted model outcome.
A sensitivity analysis was conducted to assess impact on 
model predictions of including a 5-year age gap in sexual 
partnering between men and women. A  second sensitivity 
analysis assessed impact of including the 1976–1980 NHANES 
round in model fitting.
RESULTS
The model produced robust fits to HSV-2 seroprevalence of the 
10 NHANES rounds (Figures 1–3), and to US demographics 
(Supplementary Figure 2). However, compared to the 1988–
1994 NHANES round, the model tended to slightly overesti-
mate the seroprevalence among women 45–64  years old, and 
to underestimate the seroprevalence among men aged 30–39 
and 75–79 years. Figure 3 shows the model-predicted histor-
ical and future evolution of seroprevalence in those 15–49 years 
old in comparison to NHANES rounds. In women and men, 
seroprevalence increased progressively from 1950 through the 
early 1980s, but then declined year by year, a decline projected 
to continue (but slowly) for the next 3 decades (Figure 3A). In 
women, seroprevalence was 19.9% in 1960, increased to 23.6% 
by 1970, peaked at 25.9% in 1984, but declined to 16.9% by 
2020 and 10.5% by 2050. In men, seroprevalence was 11.6% 
in 1960, increased to 13.3% by 1970, peaked at 14.2% in 1983, 
but declined to 9.6% by 2020 and 6.5% by 2050. Seroprevalence 
was approximately 75% higher in women than men throughout 
1950–2050.
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In the total (women and men) population of 15- to 49-year-
olds, seroprevalence was 15.7% in 1960, increased to 18.4% by 
1970, peaked at 19.9% in 1983, but declined to 13.2% by 2020 
and 8.5% by 2050 (Figure 3B). Between 1950 and 1983, sero-
prevalence increased by 58%, but then declined by 34% between 
1983 and 2020, and by 57% by 2050. Similar trends were found 
in those aged ≥15 years (Supplementary Figure 3).
Figure 4 shows evolution of incidence rate in the 15- to 
49-year-old population. In women and men, incidence rate 
peaked around 1970 and declined thereafter, with the decline 
accelerating between 1980 and 2010 (Figure 4A). In women, at 
peak in 1972, incidence rate was 16.8 per 1000 person-years, 
but declined by 62% to 6.4 in 2020, and by 74% to 4.4 in 2050. 
In men, at peak in 1969, the incidence rate was 7.8 per 1000 
person-years, but declined by 55% to 3.5 in 2020, and by 65% 
to 2.7 in 2050. In the total 15- to 49-year-old population, at 
peak in 1971, incidence rate was 11.9 per 1000 person-years, 
but declined by 59% to 4.9 in 2020, and by 70% to 3.5 in 2050 
(Figure 4B). Similar trends were found in those aged ≥15 years 
(Supplementary Figure 4).
Figure 5 shows the annual number of new infections (ab-
solute incidence). In women and men, incidence increased 
progressively from 1950 through the late 1970s, but then de-
clined year by year, with the decline accelerating between 1980 
and 2010 (Figure 5A). In women, at peak in 1979, there were 







































































































































































































































































Figure 1. Fitting of the age-specific distribution of herpes simplex virus type 2 (HSV-2) seroprevalence among women in the United States. The fitted HSV-2 seroprevalence 
in each 5-year age band, compared to the National Health and Nutrition Examination Survey (NHANES) data from 1988 to 2016.
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and was projected to decline to 347 000 by 2050. In men, at peak 
in 1978, there were 353 000 new infections, declining to 245 000 
by 2020 and 231 000 by 2050.
In the total 15- to 49-year-old population, at peak in 1978, there 
were 1 002 000 new infections, but declined to 647 000 by 2020 
and 578 000 by 2050 (Figure 5B). A similar pattern was observed 
in the total population aged ≥15 years (Supplementary Figure 5). 
At peak in 1978, there were 1 033 000 new infections, declining 
to 667 000 by 2020 and 600 000 by 2050. The cumulative number 
of ever-infected individuals since 1950 was 17 227 000 by 1970, 
27 179 000 by 1980, 60 502 000 by 2020, and 78 384 000 by 2050.
Figures 6 and 7 show the temporal evolution of seroprev-
alence and incidence rate, respectively, in the different age 
groups, indicating a “youth cohort” phenomenon in those aged 
15–34 years sometime between 1960 and the mid-1980s. Risk 
of infection (equivalent to incidence rate) soared in this age 
bracket at this time due to infection seeding within this age 
group (Figure 7). In 1970, incidence rate (per 1000 person-
years) among 20- to 24-year-olds was 24.2 in women and 12.7 
in men, but in 2020, it was only 9.2 in women and 5.7 in men.
A distinctive mark of this cohort effect is that seropreva-
lence between 1960 and 1990 was higher in middle-aged than 
in older adults (Figure 6); persons in this “youth cohort” ag-
gregated in a 3-decade time span more cumulative risk of 
infection than older adults aggregated over their lifetime. 
















































































































































































































































































Figure 2. Fitting of the age-specific distribution of herpes simplex virus type 2 (HSV-2) seroprevalence among men in the United States. The fitted HSV-2 seroprevalence 
in each 5-year age band, compared to the National Health and Nutrition Examination Survey (NHANES) data from 1988 to 2016.
HSV-2 Infection in the United States • ofid • 5
monotonically with age, as expected for a “typical” HSV-2 
epidemiology.
Figure 7 illustrates the consistency in the age-specific pat-
tern of incidence rate over time. Throughout 1950–2050, inci-
dence rate increased rapidly following sexual debut, reached its 
maximum among 20- to 24-year-olds, remained rather stable 
for 25- to 34-year-olds, and declined rapidly among those aged 
≥35 years. For instance, in 2020, 78% of total infections were ac-
quired by those aged 15–34 years. As for seroprevalence, other 
than the “youth cohort” generation, it increased steadily with 
age, most rapidly for 15- to 34-year-olds (Figure 6), reflecting 
the incidence rate pattern (Figure 7).
Supplementary Figure 6 shows results of the uncertainty 
analysis for the temporal evolution of seroprevalence, incidence 
rate, and annual number of new infections. The analysis af-
firmed the above findings.
Supplementary Figure 7 shows results of the sensitivity anal-
ysis including a 5-year age gap in sexual partnering between 
men and women. Predictions were affirmed but with slight 
quantitative differences; the incidence rate for women and men 
peaked in the mid-1970s instead of the early 1970s, and peaked 
in those aged 25–29  years instead of those aged 20–24  years. 
The sensitivity analysis forcing inclusion of the 1976–1980 
NHANES round in model fitting produced inferior fitting met-
rics (Supplementary Figure 8) and spurious predictions that 
contradicted available evidence (see Discussion).
DISCUSSION
Results indicate an evolving epidemiology (rapidly at times) for 
HSV-2 infection in the US. The current infection pattern im-
plicitly reflects 2 distinct experiences of 2 generations. The ep-
idemic expanded after World War II and accelerated post-1960 
(Figure 5). For those aged 15–34 years sometime between 1960 
and the mid-1980s, a time often associated with the “sexual rev-
olution” and introduction of “the pill” [48, 49], risk of infection 
was high leading to high incidence and seroprevalence for this 
specific (“youth cohort”) generation (Figures 3–7). At peak in-
cidence in late 1970s, 1 million infections occurred every year, 
nearly two-thirds of which were among women.
Nonetheless, by the mid-1980s, notably when HIV/AIDS 
was first recognized [50], risk of infection went into a steep 
decline for 3 decades before settling into a slowly declining 
pattern at present (Figure 4). Even though the US population 
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Figure 3. Temporal evolution of herpes simplex virus type 2 (HSV-2) seroprevalence in the United States. A, Estimated HSV-2 seroprevalence for women and men 
aged 15–49 years, compared to the National Health and Nutrition Examination Survey (NHANES) data. B, Estimated HSV-2 seroprevalence in the total population aged 
15–49 years, compared to NHANES data.
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expanded substantially since the 1980s (Supplementary Figure 
2), the rapid decline in incidence rate more than compen-
sated for the larger influx of new susceptibles—there were 
only 667 000 new infections in 2020, two-thirds the number 
of infections in 1978 at the epidemic peak (Figure 5 and 
Supplementary Figure 5).
Commercial tests discriminating HSV-2 from HSV-1 anti-
bodies became widely available only in the 1990s. By 1999–
2001, a number of tests were approved by the US Food and Drug 
Administration [51, 52], and seroprevalence measures began to 
proliferate in the literature. Early measures identified high levels 
of approximately 20% in the general population [1], leading to 
alarming projections for epidemic expansion [53, 54] that never 
materialized. To the contrary, repeated NHANES rounds have 
shown declining seroprevalence (Figure 3) [19–22, 28]. Our 
findings indicate that seroprevalence measures from that earlier 
era largely reflected the demographic contribution of the high-
incidence “youth cohort” generation, whereas subsequent se-
roprevalence measures increasingly reflected the contribution 
of the low-incidence younger cohorts—earlier projections [53, 
54] erred for not recognizing the implied and distinct dynamics 
of the 2 generations. As the demographic contribution of the 
“youth cohort” generation faded by 2010, HSV-2 epidemiology 
settled into a somewhat stable seroprevalence, a pattern (based 
on current trends) that is projected to continue for the next 3 
decades (Figure 3).
A highlight of the above results is the subtle role of sexual 
behavior change in driving the epidemiology. A change in pop-
ulation sexual behavior, whether it is a change in the sexual 
partnering rates and/or structure of the sexual networks, 
translates first into a change in incidence rate, then absolute 
incidence, and lastly seroprevalence (Figures 3–5)—a seroprev-
alence pattern at a given point in time is a delayed manifestation 
of behavior change 2 decades earlier. Therefore, emphasis on 
examining trends based only on observed seroprevalence is in-
adequate and will miss opportunities for prevention at the right 
time. There should be more emphasis on assessing trends of in-
cidence rate of HSV-2 infection and its disease sequalae to be 
able to capture changes in sexual behavior patterns at the right 
time and address them with appropriate interventions.
Despite the major epidemic transition over the last few dec-
ades, HSV-2 epidemiology appears to be stabilizing with key 
features (Figures 3–7). Incidence will persist at >600 000 new 
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Figure 4. Temporal evolution of herpes simplex virus type 2 (HSV-2) incidence rate in the United States. A, Estimated HSV-2 incidence rate for women and men aged 
15–49 years. B, Estimated HSV-2 incidence rate in the total population aged 15–49 years.
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infections will be added to the population by 2050, in addition 
to the currently prevalent 47 million infections. Seroprevalence 
will remain >10% among women and >6% among men. 
Incidence rate (per 1000 person-years) will hover around 5 for 
women and 3 for men (Figure 4). Women will continue to be 
disproportionately affected. Those 20–34 years of age will en-
dure the highest incidence rate and absolute incidence, with 
about three-quarters of infections occurring among them. Of 
note is that these estimates assume continuation of current 
trends in population sexual behavior over the coming 3 dec-
ades. Increases in population sexual behavior in the future will 
drive even higher incidence. This demonstrates how tenuous is 
HSV-2 control and supports the need for interventions that can 
tackle infection acquisition and transmission.
At present, there is no national program specific for genital 
herpes prevention and control given lack of a prevention mo-
dality, such as a vaccine [20, 55]. Our findings demonstrate 
the need for prophylactic and therapeutic vaccines, a current 
focus of ongoing international effort spearheaded by the World 
Health Organization [56–58]. Several vaccine candidates are 
already in phase 1 and 2 trials [56, 59]. An example is a ther-
apeutic candidate that demonstrated sustainable reductions in 
shedding and lesions over 12 months, with no serious adverse 
events [23, 56, 59]. While available prevention modalities, such 
as condoms and antiviral therapy, are insufficient to control 
infection spread, vaccination is perhaps the only feasible stra-
tegic approach to control transmission and to curb the clinical, 
psychosexual, and economic burden of this infection [26, 60]. 
A  recent modeling study assessed the impact of both HSV-2 
prophylactic and therapeutic vaccination in the US [26]. The 
study showed that a therapeutic vaccine of intermediate efficacy 
can reduce HSV-2 incidence by >10% and avert 76 000 infec-
tions per year. Meanwhile, a prophylactic vaccine of interme-
diate efficacy can reduce HSV-2 incidence by >50% and avert 
>350 000 infections per year. The impact of these vaccines was 
found to be optimal by prioritizing them to young adults and 
those at higher risk of infection.
The predicted epidemic evolution and declines in seroprev-
alence are in concordance with the historical pattern of gen-
ital herpes diagnosis [61] and statistical analyses of NHANES 
rounds [19–22]. Our results are, however, inconsistent 
with the seroprevalence of the 1976–1980 NHANES round 
(Supplementary Figures 9 and 10) [17] and a trend analysis 
using this round to report increasing seroprevalence, partic-
ularly among youth, between the 1976–1980 and 1988–1994 
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Figure 5. Temporal evolution of new herpes simplex virus type 2 (HSV-2) infections in the United States. A, Estimated annual number of new HSV-2 infections for women 
and men aged 15–49 years. B, Estimated annual number of new HSV-2 infections in the total population aged 15–49 years.
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sensitivity analyses (eg, Supplementary Figure 8), we could 
not produce the 1976–1980 round seroprevalence, though 
the model robustly and consistently fitted all other 10 rounds 
(Figures 1–3).
While earlier modeling studies, with input data including only 
the 1976–1980 and 1988–1994 rounds, projected increasing se-
roprevalence over time [53, 54], these projections contradicted 
what actually occurred (Figure 3) [19–22]. It seems implausible 
that sexual risk behavior underwent a sudden transient surge 
during the mid-to-late 1980s and early 1990s to drive higher 
incidence, exactly when it was expected to decline considering 
recognition of HIV/AIDS [50], launch of national prevention 
programs with focus on youth [62], doubling of condom use 
[63], and declines in HIV [64] and sexually transmitted infec-
tion incidence [65, 66]. These lines of evidence suggest that the 
reported 1976–1980 round seroprevalence underestimated ac-
tual seroprevalence, particularly among youth, and by as much 
as 30% (Supplementary Figure 10). While this discrepancy re-
mains unresolved, there was a change in the serological testing 
protocol between the 1976–1980 round and subsequent rounds 
[17, 18]. For NHANES 1976–1980, a non-type-specific enzyme-
linked immunoassay was applied prior to testing positive spe-
cimens with a type-specific HSV-2 test [17, 67–69]. It could 
be that persons with low antibody titers or recent infection 
evaded infection detection [17, 70, 71]. Conversely, in subse-
quent rounds, seropositivity was directly tested for using a type-
specific immunodot assay [18]. It remains unknown whether 
differences in sampling weights, or in response rate and survey 
adjustments, also contributed to this discrepancy [17, 18, 72]. 
This discrepancy argues for reexamination of stored sera of that 
round, or other stored sera from that era, and testing it using 
current gold-standard methods to clarify actual seroprevalence.
Limitations may have affected this study. Model projections 
are conditioned on quality of input data. Future projections 
were generated by fitting the model to past and current data, 
which may not hold as sexual behavior could change from one 
generation to another. These projections could also be influ-
enced by factors that are difficult to predict at present, such 
Age group
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Figure 6. Age-specific distribution of herpes simplex virus type 2 (HSV-2) seroprevalence in the United States. A, Estimated age-specific distribution of HSV-2 seroprev-
alence among women in 1960, 1970, 1980, 1990, 2020, and 2050. B, Estimated age-specific distribution of HSV-2 seroprevalence among men in 1960, 1970, 1980, 1990, 
2020, and 2050.
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as roll-out of interventions/vaccines. HSV-2 shedding was as-
sumed to continue at a fixed frequency, but evidence suggests 
that shedding declines with time [73]. HSV-2 infectiousness 
was assumed invariable despite symptoms, but this is probably 
of limited impact as most shedding is asymptomatic [4, 7, 74]. 
We did not investigate implications on disease outcomes such 
as genital ulcer disease and neonatal herpes, nor the impact on 
the HIV epidemic given the existing evidence supporting syn-
ergy between HIV and HSV-2 infections [11–16]. However, the 
present model provides a framework that could be extended to 
investigate and estimate HSV-2 disease burden and impact on 
the HIV epidemic.
This study has strengths. We used an elaborate yet minimalist 
model to capture the complex transmission dynamics. This is 
(to our knowledge) the first such study to analytically model the 
intricate epidemiology of this infection and its transition over 
a century, at a level of detail not amenable to empirical studies. 
Model outcomes fitted data robustly with predicted trends 
matching actual trends. The model was anchored on quality 
data for HSV-2 natural history and transmission. Importantly, 
the model was grounded on >3 decades of standardized and na-
tionally representative population-based NHANES data [28]. 
Remarkably, with such rigorous and large-scale data input, 
model predictions were well-constrained, limiting uncer-
tainty around predictions, despite assuming wide uncertainty 
intervals for the model parameters (Supplementary Figure 6). 
Findings were also affirmed by the sensitivity analyses.
In conclusion, the US HSV-2 epidemic underwent a major 
transition over a century, leading to 2 distinct experiences for 
2 generations. From 1950 to the mid-1980s, the epidemic ex-
panded massively to add 30 million new infections and to af-
fect nearly a quarter of the US population. From the mid-1980s, 
however, the epidemic reversed course with rapid declines, 
followed by stabilization that is projected to continue over the 
next 3 decades. Despite epidemic decline, incidence will persist 
at >600  000 infections every year, adding close to 20 million 
new infections by 2050. These findings highlight the scale of the 
HSV-2 burden in the US and demonstrate the need for con-
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Figure 7. Age-specific distribution of herpes simplex virus type 2 (HSV-2) incidence rate in the United States. A, Estimated age-specific distribution of HSV-2 incidence 
rate among women in 1960, 1970, 1980, 1990, 2020, and 2050. B, Estimated age-specific distribution of HSV-2 incidence rate among men in 1960, 1970, 1980, 1990, 2020, 
and 2050.
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Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
Notes
Author contributions. H. H. A. and I. A. designed, coded, and param-
eterized the mathematical model, conducted the analyses, and wrote the 
first draft of the article. S. F. A. and R. O. contributed to the modeling ana-
lyses. H.  C.  supported the model parameterization, conducted statistical 
analyses, and participated in the drafting of the article. L.  J. A. conceived 
and led the design of the study and model, analyses, and drafting of the ar-
ticle. All authors have read and approved the final article.
Acknowledgments. The authors gratefully acknowledge Professor 
Emeritus Rhoda Ashley Morrow from the University of Washington for her 
valuable insights about herpes simplex virus diagnostic methods. The au-
thors are also grateful for the administrative support of Ms Adona Canlas. 
The model computer codes programmed in MATLAB can be obtained by 
contacting the authors.
Disclaimer. The findings achieved herein are solely the responsibility of 
the authors. 
Financial support. H. H. A. and R. O. acknowledge the joint support of 
Qatar University and Marubeni (M-QJRC-2020–5). This publication was 
also made possible by National Priorities Research Program grant number 
9-040-3-008 from the Qatar National Research Fund (a member of Qatar 
Foundation). The authors are also grateful for pilot funding provided by 
the Biomedical Research Program and infrastructure support provided by 
the Biostatistics, Epidemiology, and Biomathematics Research Core, both at 
Weill Cornell Medicine in Qatar.
Potential conflicts of interest. All authors: No reported conflicts of 
interest. 
All authors have submitted the ICMJE Form for Disclosure of Potential 
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex 
virus types 2 and 1: a global review. J Infect Dis 2002; 186(Suppl 1):S3–28.
2. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing 
world. Herpes 2004; 11(Suppl 1):24A–35A.
3. Looker KJ, Magaret AS, Turner KM, et al. Global estimates of prevalent and inci-
dent herpes simplex virus type 2 infections in 2012. PLoS One 2015; 10:e114989.
4. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex 
virus among symptomatic and asymptomatic persons with HSV-2 infection. 
JAMA 2011; 305:1441–9.
5. James  C, Harfouche  M, Welton  NJ, et  al. Herpes simplex virus: global infec-
tion prevalence and incidence estimates, 2016. Bull World Health Organ 2020; 
98:315–29.
6. Nahmias AJ, Dowdle WR, Naib ZM, et al. Genital infection with type 2 herpes 
virus hominis. A  commonly occurring venereal disease. Br J Vener Dis 1969; 
45:294–8.
7. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex 
virus reactivation in immunocompetent adults. J Infect Dis 2008; 198:1141–9.
8. James  SH, Kimberlin  DW. Neonatal herpes simplex virus infection. Infect Dis 
Clin North Am 2015; 29:391–400.
9. Looker KJ, Magaret AS, May MT, et al. First estimates of the global and regional 
incidence of neonatal herpes infection. Lancet Glob Health 2017; 5:e300–9.
10. Mindel A, Marks C. Psychological symptoms associated with genital herpes virus 
infections: epidemiology and approaches to management. CNS Drugs 2005; 
19:303–12.
11. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more 
important role than any other sexually transmitted infection in driving HIV prev-
alence in Africa. PLoS One 2008; 3:e2230.
12. Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent 
HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect 
Dis 2017; 17:1303–16.
13. Looker KJ, Welton NJ, Sabin KM, et al. Global and regional estimates of the con-
tribution of herpes simplex virus type 2 infection to HIV incidence: a population 
attributable fraction analysis using published epidemiological data. Lancet Infect 
Dis 2020; 20:240–9.
14. Omori  R, Abu-Raddad  LJ. Sexual network drivers of HIV and herpes simplex 
virus type 2 transmission. AIDS 2017; 31:1721–32.
15. Kouyoumjian SP, Heijnen M, Chaabna K, et al. Global population-level associa-
tion between herpes simplex virus 2 prevalence and HIV prevalence. AIDS 2018; 
32:1343–52.
16. Abu-Raddad LJ, Schiffer JT, Ashley R, et al. HSV-2 serology can be predictive of 
HIV epidemic potential and hidden sexual risk behavior in the Middle East and 
North Africa. Epidemics 2010; 2:173–82.
17. Johnson RE, Nahmias AJ, Magder LS, et al. A seroepidemiologic survey of the 
prevalence of herpes simplex virus type 2 infection in the United States. N Engl J 
Med 1989; 321:7–12.
18. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the 
United States, 1976 to 1994. N Engl J Med 1997; 337:1105–11.
19. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and 
type 2 seroprevalence in the United States. JAMA 2006; 296:964–73.
20. Fanfair RN, Zaidi A, Taylor LD, et al. Trends in seroprevalence of herpes sim-
plex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 
49 years—United States, 1988 to 2010. Sex Transm Dis 2013; 40:860–4.
21. McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of herpes 
simplex virus type 1 and type 2 in persons aged 14–49: United States, 2015–2016. 
NCHS Data Brief 2018: 304:1–8.
22. Chemaitelly H, Nagelkerke N, Omori R, Abu-Raddad LJ. Characterizing herpes 
simplex virus type 1 and type 2 seroprevalence declines and epidemiological as-
sociation in the United States. PLoS One 2019; 14:e0214151.
23. Gottlieb  SL, Giersing  BK, Hickling  J, et  al; HSV Vaccine Expert Consultation 
Group. Meeting report: initial World Health Organization consultation on herpes 
simplex virus (HSV) vaccine preferred product characteristics, March 2017. 
Vaccine 2019; 37:7408–18.
24. Johnston C, Koelle DM, Wald A. Current status and prospects for development of 
an HSV vaccine. Vaccine 2014; 32:1553–60.
25. Sandgren  KJ, Truong  NR, Smith  JB, et  al. Vaccines for herpes simplex: recent 
progress driven by viral and adjuvant immunology. Methods Mol Biol 2020; 
2060:31–56.
26. Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Epidemiological impact of novel pre-
ventive and therapeutic HSV-2 vaccination in the United States: mathematical 
modeling analyses. Vaccines 2020; 8:366.
27. Alsallaq RA, Schiffer JT, Longini IM Jr, et al. Population level impact of an im-
perfect prophylactic vaccine for herpes simplex virus-2. Sex Transm Dis 2010; 
37:290–7.
28. Centers for Disease Control and Prevention, National Center for Health Statistics. 
National Health and Nutrition Examination Survey, 1976–2016. Available at: 
https://wwwn.cdc.gov/nchs/nhanes/.  Accessed 28 May 2021. 
29. Abu-Raddad LJ, Longini IM Jr. No HIV stage is dominant in driving the HIV ep-
idemic in sub-Saharan Africa. AIDS 2008; 22:1055–61.
30. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels 
the spread of both diseases in sub-Saharan Africa. Science 2006; 314:1603–6.
31. Ayoub HH, Chemaitelly H, Abu-Raddad LJ. Characterizing the transitioning ep-
idemiology of herpes simplex virus type 1 in the USA: model-based predictions. 
BMC Med 2019; 17:57.
32. Liljeros F, Edling CR, Amaral LA, et al. The web of human sexual contacts. Nature 
2001; 411:907–8.
33. Watts CH, May RM. The influence of concurrent partnerships on the dynamics of 
HIV/AIDS. Math Biosci 1992; 108:89–104.
34. Barrat  A, Barthélemy  M, Pastor-Satorras  R, Vespignani  A. The architecture of 
complex weighted networks. Proc Natl Acad Sci U S A 2004; 101:3747–52.
35. Boccaletti  S, Latora  V, Moreno  Y, et  al. Complex networks: structure and dy-
namics. Phys Rep 2006; 424:175–308.
36. Watts  DJ, Strogatz  SH. Collective dynamics of ‘small-world’ networks. Nature 
1998; 393:440–2.
37. Garnett GP, Anderson RM. Balancing sexual partnerships in an age and activity 
stratified model of HIV transmission in heterosexual populations. IMA J Math 
Appl Med Biol 1994; 11:161–92.
38. Awad SF, Abu-Raddad LJ. Could there have been substantial declines in sexual 
risk behavior across sub-Saharan Africa in the mid-1990s? Epidemics 2014; 
8:9–17.
39. Awad SF, Sgaier SK, Tambatamba BC, et al. Investigating voluntary medical male 
circumcision program efficiency gains through subpopulation prioritization: in-
sights from application to Zambia. PLoS One 2015; 10:e0145729.
40. MATLAB. The language of technical computing. Natick, MA: MathWorks, Inc, 
2019.
HSV-2 Infection in the United States • ofid • 11
41. Centers for Disease Control and Prevention. Survey methods and analytic guide-
lines. 2016. Available at: https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.
aspx. Accessed 10 March 2021. 
42. United Nations Department of Economic and Social Affairs. World population 
prospects, the 2015 revision. New York, USA: United Nations, 2015.
43. Lagarias  JC, Reeds  JA, Wright  MH, Wright  PE. Convergence properties of the 
Nelder-Mead simplex method in low dimensions. Siam J Optim 1998; 9:112–47.
44. Ayoub HH, Al Kanaani Z, Abu-Raddad LJ. Characterizing the temporal evolution 
of the hepatitis C virus epidemic in Pakistan. J Viral Hepat 2018; 25:670–9.
45. Chemaitelly H, Awad SF, Abu-Raddad LJ. The risk of HIV transmission within 
HIV-1 sero-discordant couples appears to vary across sub-Saharan Africa. 
Epdemics 2014; 6:1–9.
46. Chemaitelly H, Awad SF, Shelton JD, Abu-Raddad LJ. Sources of HIV incidence 
among stable couples in sub-Saharan Africa. J Int AIDS Soc 2014; 17:18765.
47. Ayoub HH, Abu-Raddad LJ. Impact of treatment on hepatitis C virus transmis-
sion and incidence in Egypt: a case for treatment as prevention. J Viral Hepat 
2017; 24:486–95.
48. Allyn  D. Make love, not war: the sexual revolution: an unfettered history. 
Oxfordshire, United Kingdom: Routledge, 2016.
49. Chadwick KD, Burkman RT, Tornesi BM, Mahadevan B. Fifty years of “the pill”: 
risk reduction and discovery of benefits beyond contraception, reflections, and 
forecast. Toxicol Sci 2012; 125:2–9.
50. Greene WC. A history of AIDS: looking back to see ahead. Eur J Immunol 2007; 
37(Suppl 1):S94–102.
51. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 
and HSV-2 infection. Clin Infect Dis 2002; 35:S173–82.
52. Ashley RL. Performance and use of HSV type-specific serology test kits. Herpes 
2002; 9:38–45.
53. Fisman DN, Lipsitch M, Hook EW 3rd, Goldie SJ. Projection of the future dimen-
sions and costs of the genital herpes simplex type 2 epidemic in the United States. 
Sex Transm Dis 2002; 29:608–22.
54. Armstrong GL, Schillinger J, Markowitz L, et al. Incidence of herpes simplex virus 
type 2 infection in the United States. Am J Epidemiol 2001; 153:912–20.
55. Douglas  JM Jr, Berman SM. Screening for HSV-2 infection in STD clinics and 
beyond: a few answers but more questions. Sex Transm Dis 2009; 36:729–31.
56. World Health Organization. World Health Organization preferred product char-
acteristics for herpes 2 simplex virus vaccines. 2019. Available at: https://apps.
who.int/iris/bitstream/handle/10665/312344/9789241515580-eng.pdf. Accessed 
28 May 2021. 
57. Gottlieb  SL, Giersing  B, Boily  MC, et  al. Modelling efforts needed to advance 
herpes simplex virus (HSV) vaccine development: key findings from the World 
Health Organization Consultation on HSV vaccine impact modelling. Vaccine 
2019; 37:7336–45.
58. Gottlieb SL, Deal CD, Giersing B, et al. The global roadmap for advancing devel-
opment of vaccines against sexually transmitted infections: update and next steps. 
Vaccine 2016; 34:2939–47.
59. Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of 
vaccines for herpes simplex virus. Vaccine 2016; 34:2948–52.
60. Giersing BK, Vekemans J, Nava S, et al; WHO Product Development for Vaccines 
Advisory Committee. Report from the World Health Organization’s Third 
Product Development for Vaccines Advisory Committee (PDVAC) meeting, 
Geneva, 8-10th June 2016. Vaccine 2019; 37:7315–27.
61. Becker TM, Blount JH, Guinan ME. Genital herpes infections in private practice 
in the United States, 1966 to 1981. JAMA 1985; 253:1601–3.
62. Ku LC, Sonenstein FL, Pleck JH. The association of AIDS education and sex ed-
ucation with sexual behavior and condom use among teenage men. Fam Plann 
Perspect 1992; 24:100–6.
63. Sonenstein FL, Pleck JH, Ku LC. Sexual activity, condom use and AIDS awareness 
among adolescent males. Fam Plann Perspect 1989; 21:152–8.
64. Rosenberg PS, Biggar RJ. Trends in HIV incidence among young adults in the 
United States. JAMA 1998; 279:1894–9.
65. Centers for Disease Control and Prevention. Summary of notifiable diseases, 
United States, 1997. MMWR Morb Mortal Wkly Rep 1998; 46:ii-vii, 3–87.
66. Groseclose SL, Zaidi AA, DeLisle SJ, et al. Estimated incidence and prevalence of 
genital Chlamydia trachomatis infections in the United States, 1996. Sex Transm 
Dis 1999; 26:339–44.
67. Lee  FK, Coleman  RM, Pereira  L, et  al. Detection of herpes simplex virus type 
2-specific antibody with glycoprotein G. J Clin Microbiol 1985; 22:641–4.
68. Lee FK, Pereira L, Griffin C, et al. A novel glycoprotein for detection of herpes 
simplex virus type 1-specific antibodies. J Virol Methods 1986; 14:111–8.
69. Coleman  RM, Pereira  L, Bailey  PD, et  al. Determination of herpes simplex 
virus type-specific antibodies by enzyme-linked immunosorbent assay. J Clin 
Microbiol 1983; 18:287–91.
70. Ashley  RL, Militoni  J, Lee  F, et  al. Comparison of Western blot (immunoblot) 
and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to 
herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988; 26:662–7.
71. Nahmias AJ, Lee FK, Pereira L, et al. Monoclonal antibody immunoaffinity puri-
fied glycoproteins for the detection of herpes simplex virus type 1 and type 2 spe-
cific antibodies in serum. Human herpesvirus infections. New York: Raven Press, 
1986:203–9.
72. Forthofer RN. Investigation of nonresponse bias in NHANES II. Am J Epidemiol 
1983; 117:507–15.
73. Ramchandani M, Selke S, Magaret A, et al. Prospective cohort study showing per-
sistent HSV-2 shedding in women with genital herpes 2 years after acquisition. 
Sex Transm Infect 2018; 94:568–70.
74. Gnann JW Jr, Whitley RJ. Genital herpes. N Engl J Med 2016; 375:666–74.
